Slow Drug Release Novel Torsemide Formulation May help patients with bladder sensitivity
SOAANZ is an FDA approved drug to treat edema associated with heart failure and renal diseases.
SOAANZ May Help Patients Who Experience Worsening Bladder Problem With The Use Of Generic Loop Diuretics.
If you are a heart failure patient experiencing bladder issues from generic loop diuretics. SOAANZ may help.
Key Benefits Of SOAANZ:
SOAANZ does not cause excessive or acute urination but retains diuretic effectiveness.
Have a look at some key benefits of SOAANZ:
Releases Drug Slowly
Causes No Excessive Urination
Maintains Natriuresis For Up to 8 hours.
Highlights Of Prescribing Information
These highlights do not include all the information needed to use SOAANZ® safely and effectively. See full prescribing information for SOAANZ.
SOAANZ (torsemide) tablets, for oral use
Indications And Usage
SOAANZ is a loop diuretic indicated in adults for the treatment of edema associated with heart failure or renal disease. (1)
Dosage And Administration
The recommended initial dose is 20 mg orally once daily. Titrate dose by approximately doubling until desired diuretic response is obtained. Doses above 200 mg have not been studied.(2)
Tablets: 20 mg, 40 mg and 60 mg (3)
Hypersensitivity to SOAANZ, anuria, and hepatic coma. (4)
Hypotension and worsening renal function: monitor volume status and renal function periodically (5.1)
Electrolyte and metabolic abnormalities: monitor serum electrolytes and blood glucose periodically. (5.2)
Ototoxicity (5.3, 7.6)
Discontinuation of therapy due to adverse reactions occurred in 6% of patients treated with SOAANZ (6.1).
To report SUSPECTED ADVERSE REACTIONS, contact Sarfez Pharmaceuticals Inc. at 1-703-627-1934 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Non-steroidal anti-inflammatory drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects; risk of renal impairment. (7.1)
CYP2C9: Concomitant use with CYP2C9 inhibitors can decrease torsemide clearance. Torsemide may affect the efficacy and safety of sensitive CYP2C9 substrates or of substrates with a narrow therapeutic range, such as warfarin or phenytoin. (7.2)
Cholestyramine: Decreased exposure of SOAANZ. (7.3)
Organic anion drugs: may decrease diuretic activity of SOAANZ. (7.4)
Lithium: Risk of lithium toxicity. (7.5)
Renin-angiotensin inhibitors: Increased risk of hypotension and renal impairment. (7.7)
Radiocontrast agents: Increased risk of renal toxicity. (7.8)
Corticosteroids and ACTH: Increased risk of hypokalemia. (7.9)